Greetings and welcome aboard:
I'll speak for myself, and Ram can chime in. As a little research shows, this is a product with tremendous potential. Again, the key word is potential. I got involved when the company was being spun off and have been patiently waiting for them to move past setup phase and start selling gazillions of the Stat-K. There are still some roadblocks to that goal, but they have a product that works, it has FDA approval and are putting together overseas marketing. Biotrack would provide immediate cash infusion to take the strain off fund-raising.
Wouldn't $8 be nice ... shoot at this point, wouldn't $3 be nice (gg). For PDTK to reach $8, assuming the total number of shares reaches and remains at 10 million after the Biotrack conversion, the company would have to produce $4 million in profit per year (that's assuming a PE of 20...if you like those loftier biomed PEs, feel free to factor your own). The Biotrack is expected to bring in $1 million in profit its first year, or at a 20 PE, we're look at an expectation of $2 per share. Any progress on the Stat-K, either in sales or an FDA variance on the technical applications, would also boost the share price.
That's where things are right now. We're one acquisition away from a six-fold jump in value (or more if there are still a lot of shorts in here). Please keep in mind that this is all by guess and by golly, based on information gleaned from the company. And since some of the PDTI folks check in from time to time, if they see somplace I misspoke, I'd be grateful if they could clarify. Won't offend me in the least.
I'll let Ram take over now,
Good trading,
Chick in (somewhat soggy) N.C. |
